Log in

NASDAQ:ELGXEndologix Stock Price, Forecast & News

+0.13 (+14.61 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $1.02
50-Day Range
MA: $0.82
52-Week Range
Now: $1.02
Volume690,216 shs
Average Volume434,559 shs
Market Capitalization$19.55 million
P/E RatioN/A
Dividend YieldN/A
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More
Endologix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:ELGX



Sales & Book Value

Annual Sales$143.37 million
Book Value$3.56 per share


Net Income$-64,760,000.00


Market Cap$19.55 million
Next Earnings Date8/13/2020 (Estimated)

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Endologix (NASDAQ:ELGX) Frequently Asked Questions

How has Endologix's stock been impacted by COVID-19 (Coronavirus)?

Endologix's stock was trading at $0.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ELGX shares have increased by 8.5% and is now trading at $1.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endologix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endologix.

When is Endologix's next earnings date?

Endologix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Endologix.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) posted its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to the consensus estimate of $28.50 million. Endologix had a negative return on equity of 63.96% and a negative net margin of 44.65%. View Endologix's earnings history.

When did Endologix's stock split? How did Endologix's stock split work?

Endologix's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

What guidance has Endologix issued on next quarter's earnings?

Endologix issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $28.5-28.5 million, compared to the consensus revenue estimate of $30.73 million.

What price target have analysts set for ELGX?

3 brokers have issued twelve-month price targets for Endologix's stock. Their forecasts range from $1.00 to $7.00. On average, they anticipate Endologix's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price. View analysts' price targets for Endologix.

Has Endologix been receiving favorable news coverage?

News articles about ELGX stock have trended positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endologix earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutEndologix.

Are investors shorting Endologix?

Endologix saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 490,900 shares, an increase of 30.2% from the April 30th total of 377,000 shares. Based on an average daily volume of 359,500 shares, the short-interest ratio is currently 1.4 days. Approximately 3.0% of the shares of the stock are short sold. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Who are Endologix's major shareholders?

Endologix's stock is owned by a number of institutional and retail investors. Top institutional investors include Deutsche Bank AG (2.63%), NEA Management Company LLC (1.30%), Invesco Ltd. (0.78%), Parametric Portfolio Associates LLC (0.38%), King Wealth (0.34%) and Wedbush Securities Inc. (0.20%). Company insiders that own Endologix stock include Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View institutional ownership trends for Endologix.

Which major investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Endologix.

Which major investors are buying Endologix stock?

ELGX stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Invesco Ltd., King Wealth, and Wedbush Securities Inc.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III, and Vaseem Mahboob. View insider buying and selling activity for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $1.02.

How big of a company is Endologix?

Endologix has a market capitalization of $19.55 million and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.

What is Endologix's official website?

The official website for Endologix is www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.